Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report)’s share price fell 0.6% on Monday . The company traded as low as $0.76 and last traded at $0.80. 12,766 shares were traded during mid-day trading, a decline of 51% from the average session volume of 25,988 shares. The stock had previously closed at $0.80.
Analyst Ratings Changes
Separately, Maxim Group reduced their price objective on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.
Read Our Latest Research Report on Indaptus Therapeutics
Indaptus Therapeutics Stock Down 0.6 %
About Indaptus Therapeutics
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Read More
- Five stocks we like better than Indaptus Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Manufacturing Stocks Investing
- Price Targets on NVIDIA Rise in Front of Earnings
- Buy P&G Now, Before It Sets A New All-Time High
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
